ABP 501 for Plaque Psoriasis

"There is existing clinical evidence backing ABP 501's safety, resulting in a score of 3."

"Presently, this clinical trial is not looking for new participants. The study was initially posted on October 4th 2021 and was most recently edited on November 16th 2022. For individuals searching for other studies, there are presently 179 studies actively seeking enrolment from patients with psoriasis vulgaris (plaque psoriasis) and 52 studies recruiting ABP 501 patients."

"This study is taking place at 58 different sites, which are situated in locations such as Mason, Surrey and Palm Springs. To limit the amount of travel required, it is best to select a trial location that is close to your home."

"Unfortunately, this particular clinical trial is not enrolling patients at the moment. As stated on clinicaltrials.gov, the last update was on November 16th, 2022 and the trial was originally posted October 4th, 2021. Although there are no other trials currently looking for participants, there are 231 other trials enrolling patients right now."

"This dermatology study only admits patients that have plaque psoriasis and are between 18-75 years old. There is space for around 425 individuals in the trial."

"The age range for patients eligible to enroll in this study is 18-75. Out of the 241 total clinical trials, 45 are for those under 18 and 196 are for patients 65 and over."

"The objective of this study, which will be evaluated over a Week 28 (Pre-dose and Post-dose) through Week 30 time frame, is to Area Under the Curve From Time 0 Over the Dosing Interval (AUCtau) of Adalimumab and ABP 501. Secondary outcomes include Percent Improvement in PASI From Baseline to Week 30 which is defined as The PASI is a measure of the average redness (erythema), thickness (induration), and scaliness (scaling); each graded on a 0-4 scale (0 = clear; 1-4= increasing severity)"

"The latest information shows that there are 52 clinical trials underway for ABP 501. Of these, 14 are in the final stage (Phase 3). The majority of these trials take place in London; however, there are 2122 locations worldwide where patients can participate in a trial."

"ABP 501 is a medication used to treat ankylosing spondylitis, but it can also help patients with rheumatoid arthritis, psoriatic arthritis, and polyarticular juvenile idiopathic arthritis."